T2 Biosystems CS (TTOO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -32,614 | -22,497 | -13,534 | -50,077 | -39,737 |
| Depreciation Amortization | 185 | 126 | 64 | 859 | 785 |
| Accounts receivable | -613 | 123 | -168 | 743 | 1,024 |
| Accounts payable and accrued liabilities | 2,683 | 159 | 358 | 231 | -208 |
| Other Working Capital | 2,973 | -500 | -593 | -4,042 | -3,519 |
| Other Operating Activity | 210 | 1,665 | 2,190 | 4,150 | 2,935 |
| Operating Cash Flow | $-27,176 | $-20,924 | $-11,683 | $-48,136 | $-38,720 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -192 | -166 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $-192 | $-166 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 6,302 | 2,213 | 2,203 | 52,750 | 41,020 |
| Other Financing Activity | 7,268 | 7,268 | -1 | -62 | 10,856 |
| Financing Cash Flow | $13,570 | $9,481 | $2,202 | $52,688 | $51,876 |
| Beginning Cash Position | 16,240 | 16,240 | 16,240 | 11,880 | 11,880 |
| End Cash Position | 2,634 | 4,797 | 6,759 | 16,240 | 24,870 |
| Net Cash Flow | $-13,606 | $-11,443 | $-9,481 | $4,360 | $12,990 |
| Free Cash Flow | |||||
| Operating Cash Flow | -27,176 | -20,924 | -11,683 | -48,136 | -38,720 |
| Capital Expenditure | N/A | N/A | N/A | -192 | -166 |
| Free Cash Flow | -27,176 | -20,924 | -11,683 | -48,328 | -38,886 |